In a recent investor webinar, 4DMedical Limited (FDMDF) discussed the use of its CT:VQ technology in selecting patients for lung volume reduction surgery (LVRS), a procedure aimed at improving lung function in patients suffering from severe emphysema. The discussion featured insights from Dr. Andreas Fouras, the company's CEO, and Dr. Joseph Mammarappallil, an Associate Professor of Radiology at Duke University. LVRS involves the surgical removal of the most diseased lung tissue, allowing healthier lung areas to function more effectively. Given the significant surgical risks associated with LVRS, careful patient selection is paramount. The webinar highlighted findings from a recent clinical trial that investigated the effectiveness of CT:VQ in aiding this selection process. These findings were also presented at the American Thoracic Society Conference, emphasizing the importance of utilizing advanced imaging techniques to improve surgical outcomes for patients with emphysema. The potential of CT:VQ technology to enhance patient selection criteria could lead to better management of surgical risks and improved recovery rates for patients undergoing LVRS.